Deutsches Herzzentrum Berlin

Berlin 65760

2 studies enrolling now · 17 studies all time

What they study most

Aortic Dissection, Aortic Regurgitation, Aortic Valve Disease, Aortic Valve Disorder, Aortic Valve Replacement, Aortic Valve Stenosis, Ascending Aorta Abnormality, Cardiac Surgery, Cardiac Valve Disease, Cardiovascular Disease, Cardiovascular Diseases, Graft Rejection

Studies at this site

• Valved Graft PMCF Study — Recruiting now
• CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting — Recruiting now
• SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial — Running, not enrolling
• Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction — Completed
• Trifecta™ GT Post Market Clinical Follow-up — Completed
• Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery — Completed
• Strategic MAnagement to Optimize Response To Cardiac Resynchronization Therapy Registry — Completed
• JENAVALVE AS EFS TRIAL: Pericardial TAVR Aortic Stenosis Study — Status unconfirmed
• THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study — Running, not enrolling
• The MitraClip® EXPAND Study of the Next Generation of MitraClip® Devices — Completed
• QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery — Stopped early
• ENABLE MRI (Magnetic Resonance Imaging) — Completed
• Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D — Status unconfirmed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection — Completed